The “Omics Innovation & Applications - Thailand Clinical Genomics & Precision Medicine Forum”, co-hosted by BGI Group and Bangkok Genomics Innovation Co., Ltd. (BKGI), a joint venture of BGI Genomics, recently concluded successfully in Bangkok.
Group photo of all participants at the forum.
The forum brought together more than 100 clinicians, researchers, public health representatives and industry partners from across Thailand for discussions on the application of genomics and multi-omics technologies in reproductive health, oncology precision medicine, pathogen detection, preventive health and health management.
Cao Sujie, General Manager of Asia-Pacific at BGI Genomics, delivers opening remarks.
The forum opened with remarks by Cao Sujie, General Manager of Asia-Pacific at BGI Genomics, who reviewed BGI’s development and introduced its integrated ecosystem spanning research, clinical services, technology platforms and industry-academia collaboration. He also shared BGI’s perspective on future trends in multi-omics innovation and precision medicine.
A representative from the Medical Life Sciences Institute, Department of Medical Sciences, Thailand Ministry of Public Health, reviewed the development of non-invasive prenatal testing (NIPT) in Thailand, including its clinical adoption, reimbursement pathway and local implementation experience.
In 2025, BGI Genomics, a subsidiary of BGI Group, and BKGI supported the inclusion of NIPT in Thailand’s healthcare reimbursement system, marking an important step in expanding access to advanced prenatal screening and moving the technology from early clinical introduction toward broader public health application.
Prof. Dr. Sakorn Pornprasert, Dean of the Faculty of Associated Medical Sciences at Chiang Mai University, discussed the latest developments in thalassemia screening and diagnosis.
In the field of thalassemia prevention and control, experts from Thailand’s public health and academic communities shared research findings and practical experience in genomics-based thalassemia screening and diagnosis. Prof. Dr. Sakorn Pornprasert, Dean of the Faculty of Associated Medical Sciences at Chiang Mai University, discussed evidence generated through long-read sequencing, next-generation sequencing and conventional hematological testing. His presentation highlighted how genomics-based approaches can support more accurate thalassemia screening and diagnosis, offering a reference model for birth defect prevention in high-prevalence regions.
Chulaluck Kuptanon, M.D., Queen Sirikit National Institute of Child Health, introduced the clinical value of whole-exome sequencing (WES) and whole-genome sequencing (WGS) in rare diseases and complex cases.
In rare disease screening and diagnosis, Liu Qianqi, Deputy Director of BGI Genomics Product Center, and Chulaluck Kuptanon, M.D., from Queen Sirikit National Institute of Child Health, introduced the clinical value of whole exome sequencing (WES) and whole genome sequencing (WGS) in rare diseases and complex cases. Their presentations highlighted how advanced sequencing technologies can help improve diagnostic accuracy and support treatment decisions.
Passakorn Wanchaijiraboon, M.D., Medical Oncologist, Phrapokklao Hospital Chanthaburi, shared experience in applying clinical genomics to precision cancer care.
In oncology, Passakorn Wanchaijiraboon, M.D., Medical Oncologist at Phrapokklao Hospital Chanthaburi, together with other experts in the field, shared insights into the application of clinical genomics in precision cancer care. The presentation covered companion diagnostics, molecular residual disease monitoring, and local implementation, highlighting the growing role of genomics in personalized oncology.
Wang Daxi, Principal Scientist at BGI-Research, focused on pathogen detection and antimicrobial resistance surveillance, presenting the clinical and research value of pathogen testing in respiratory infections, pathogen identification and resistance monitoring.
Yuan Ke, Product Director of Department 133111i, together with industry experts, delivered a presentation on “Preventive and Wellness Genomics.” The session illustrated a health-focused lifestyle concept and preventive healthcare pathway enabled by innovative multi-omics applications. By integrating precision multi-omics testing and intervention, life data, new internet-based healthcare models, and artificial intelligence, the presentation showed how a proactive health management paradigm can broaden and deepen traditional approaches to health management by helping prevent disease before it occurs.
Wang Yuan, Head of Technical Support, BGI Genomics Mass Spectrometry, presented BGI’s LC-MS and Time of Flight MS platforms, outlining their technical advantages and application scenarios in multi-omics research and clinical translation. Tan Zhongyu, General Manager of SIRO Center at BGI Genomics, introduced BGI’s latest automation and integrated technology platforms, presenting a new vision for the integrated application of multi-omics technologies.
The forum concluded with an expert discussion on the future of precision medicine in Thailand. Asst. Prof. Dr. Tanawan Samleerat Carraway, Genomics Laboratory Manager, MedPark Hospital, and Prof. Dr. Vorasuk Shotelersuk, M.D., FABMG, Director, Center of Excellence for Medical Genomics, Chulalongkorn University, discussed pathways for advancing precision medicine in Thailand, including clinical implementation, system development and industry collaboration.
The forum brought together stakeholders from hospitals, research institutions, public health organizations and industry to exchange views on clinical genomics and precision medicine. It provided a platform for dialogue between the medical and industrial communities and contributed practical experience and shared understanding for further advancing the clinical application of genomics and multi-omics technologies in Thailand.